CLNN · Clene Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $134K | $200K | $342K | $654K | $473K | $723K | $206K | |
| — | — | — | — | -$3.3M | — | — | |
| $23K | $43K | $70K | $121K | $26K | — | — | |
| $111K | $157K | $272K | $533K | $447K | — | — | |
| — | 78.5% | 79.53% | 81.5% | 94.5% | — | — | |
| $12.86M | $14.01M | $20.06M | $26.66M | $31.92M | $28.42M | $15.2M | |
| $8.32M | $9.23M | $13.31M | $14.42M | $16.94M | $22M | $5.15M | |
| $51.23M | — | — | — | — | $50.7M | $20.42M | |
| $21.2M | $23.28M | $33.44M | $41.19M | $48.88M | — | — | |
| -$21.07M | -$23.08M | -$33.09M | -$40.54M | -$48.41M | -$49.98M | -$20.21M | |
| — | -11541.5% | -9676.32% | -6198.78% | -10234.46% | -6912.59% | -9812.62% | |
| $2.87M | $2.68M | $4.06M | $4.56M | — | $870K | $950K | |
| $189K | $223K | $865K | $1.39M | — | — | — | |
| -$12.45M | -$3.09M | -$6.31M | -$8.96M | $18.49M | $39.81M | $1.34M | |
| -$33.51M | -$26.17M | -$39.4M | -$49.5M | -$29.92M | -$10.17M | -$18.87M | |
| $0 | $0 | $0 | $0 | $0 | -$428K | $406K | |
| -$33.51M | -$26.17M | -$39.4M | -$49.5M | -$29.92M | -$9.74M | -$19.28M | |
| — | -13086.5% | -11520.47% | -7569.42% | -6325.16% | -1347.16% | -9357.77% | |
| -$33.38M | -$26.07M | -$39.53M | -$49.51M | -$29.95M | -$9.83M | -$18.99M | |
| USD/shares | — | -$2.65 | -$5.67 | -$9.40 | -$9.20 | — | — |
| shares | — | 9.86M | 6.95M | 5.25M | 3.26M | 3.08M | 875.2K |
| shares | — | — | — | — | — | 3.08M | 875.2K |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 29 similar-size Packaged Foods companies (of 68 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2022 | FY2021 |
|---|---|---|
| Supplements Segment | $473,000 | $723,000 |
| Drugs Segment | $0 | $0 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Product | $119,000 | $237,000 | $498,000 | $329,000 | $570,000 | $176,000 |
| Royalty | $81,000 | $105,000 | $156,000 | $144,000 | $153,000 | $30,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2022 | FY2021 |
|---|---|---|
| Supplements Segment | $360,000 | $205,000 |
| Drugs Segment | -$48,769,000 | -$50,183,000 |
Operating Margin by Segment (%)
| Component | FY2022 | FY2021 |
|---|---|---|
| Supplements Segment | 76.1% | 28.4% |